pharmaphorum

FEBRUARY 22, 2021

If a causal link is shown, it could have “significant ramifications” on the use of lentiviral vectors, a type of self-inactivating virus that underpins both approved cell therapies like Novartis’ CAR-T Kymriah as well as a host of experimental therapies that involve genetic manipulation of cells. million in Europe.

Immunization 52

Immunization 52

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. Notably, 2022 saw the greatest number of RSA deals arranged, surpassing the previous record in 2017, when the first gene therapy, Novartis’s Kymriah (tisagenlecleucel), was approved and priced at $475,000.

FDA 105

FDA 105

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. It will be six years since the US FDA approval of Kymriah in August this year. Bruce Levine, PhD, co-inventor of Kymriah AZ: What is being done to realise the full potential of CAR-T therapies in solid tumours?

FDA 59

FDA Immunization 59

pharmaphorum

DECEMBER 23, 2022

Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting.

Immunization 52

Immunization Hospitals Vaccines 52

pharmaphorum

NOVEMBER 16, 2022

The debates over pricing and profits have always existed in the industry, but the arrival of CAR-T treatments , such as Kymriah (tisagenlecleucel), which is priced at $475,000 per dose, immediately raised a discussion on how far prices should be raised. However, with a price tag of €1.58 How to navigate the new climate.

131

131